Stoke Therapeutics: 3 Key Takeaways for Long-Term Investors

Source Motley_fool

Key Points

  • The FDA agreed to a multicomponent assessment using four subdomains for the key secondary endpoint on cognition and behavior.

  • All 162 enrolled patients remain active in the EMPEROR Phase III trial.

  • Top 50 sites treat half of addressable U.S. Dravet syndrome patients.

  • Motley Fool Issues Rare "Total Conviction" Buy Alert ›

On its third-quarter 2026 business update call, held on Oct. 29, 2026, Stoke Therapeutics (NASDAQ:STOK) announced alignment with the FDA on a composite endpoint for lead drug candidate Zorevunersen in Dravet syndrome. This regulatory agreement clarifies the approval pathway for the experimental medicine, which targets a rare genetic epilepsy with high unmet medical need. For long-term investors, clear clinical endpoints and full trial retention strengthen prospects for potential approval and launch in early 2028.

Three things management said stand out.

1. FDA Agreement Streamlines the Path for Zorevunersen

The New Drug Application (NDA) submission for Zorevunersen, an investigational therapy for Dravet syndrome, will use a combined cognitive and behavioral assessment. The Food and Drug Administration (FDA) agreed to evaluate key secondary endpoints using four subdomains from Vineland-3, an adaptive behavior scale.

An important outcome of our meeting was the FDA's willingness to accept a multicomponent assessment of Vineland-3 data for purposes of evaluating the key secondary endpoint related to changes in cognition and behavior.
-- Ian Smith, Chief Executive Officer

2. Zero Patient Discontinuations Strengthen Trial Data

In the EMPEROR Phase III registrational trial, 162 patients enrolled across global sites without a single participant dropping out. High patient retention preserves statistical power and signals strong caregiver commitment to the clinical program.

We ultimately enrolled 162 patients. And as I mentioned, there have been no discontinuations to date. These metrics reflect a well-designed trial, the need for better treatments, and a deeply committed community of investigators, site teams, and caregivers.
-- Dr. Barry Ticho, Chief Medical Officer

3. Concentrated Care Centers Focus Launch Strategy

Management identified 6,000 addressable pediatric patients in the U.S. living with Dravet syndrome. Half of those patients receive treatment at 50 specialized medical centers experienced in intrathecal delivery, an injection directly into the spinal canal.

Approximately half of identified U.S. patients are cared for by the top 50 sites. All 50 of those sites are experienced in administering intrathecal medicines and over half of these sites have participated in a zorevunersen study.
-- Jason Hoitt, Chief Patient Officer

Looking Ahead

Clinical progress extends into autosomal dominant optic atrophy, an inherited disorder causing vision loss. Phase I dosing for STK-002 tests whether targeting protein deficiency translates into improved sight.

OSPREY is designed to provide clinical proof of concept by testing whether increasing OPA1 protein expression with STK-002 translates into measurable effects on visual function in patients with ADOA.
-- Dr. Barry Ticho, Chief Medical Officer

Cash reserves of $358.8 million and partner reimbursements provide multiyear funding through expected commercial launch.

Along with the reimbursement we received from Biogen for zorevunersen-related expenses and a potential development milestone payment, we expect our cash position to fund our operations into early 2028.
-- Thomas Leggett, Chief Financial Officer

Should you buy stock in Stoke Therapeutics right now?

Before you buy stock in Stoke Therapeutics, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Stoke Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $305,941!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $771,325!*

Now, it’s worth noting Stock Advisor’s total average return is 719% — a market-crushing outperformance compared to 192% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 22, 2026.

The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Gold Price Today: Can XAU/USD Hold $3,500? | Mitrade AUGold approaches US$3,500 as Fed tightening fears drive sharp weekly losses. Explore XAU/USD levels, Treasury yields and the outlook for Australian traders.
Author  Mitrade Team
Nov 20, Fri
Gold approaches US$3,500 as Fed tightening fears drive sharp weekly losses. Explore XAU/USD levels, Treasury yields and the outlook for Australian traders.
placeholder
Australia’s jobs market just cracked — has the AUD/USD rate story flipped?Australia’s weakening jobs market is raising fresh questions about the RBA’s interest rate outlook and the Australian dollar. Explore why AUD/USD could be losing support, the key factors driving currency movements and what Australian forex traders should watch next.
Author  Mark Garro
Nov 20, Fri
Australia’s weakening jobs market is raising fresh questions about the RBA’s interest rate outlook and the Australian dollar. Explore why AUD/USD could be losing support, the key factors driving currency movements and what Australian forex traders should watch next.
placeholder
Market News Today Australia: VIX Surges Nearly 16%, Gold Breaks US$3,600 and US Stocks SlideVIX jumps 15.8%, Nasdaq 100 falls 2.21% and gold slips below US$3,600. Explore Anthropic’s debut and the outlook for Australian CFD traders.
Author  Mitrade Team
Nov 20, Fri
VIX jumps 15.8%, Nasdaq 100 falls 2.21% and gold slips below US$3,600. Explore Anthropic’s debut and the outlook for Australian CFD traders.
placeholder
Is Tech in a Bear Market? 20 Tech Stocks Fall Up to 76% From HighsAll 20 tech stocks on a list from financial newsletter The Kobeissi Letter trade at least 25% below record highs. CoreWeave (CRWV) leads the slide at 76%.Additionally, the S&P 500 has lost over $6 tri
Author  Beincrypto
Nov 20, Fri
All 20 tech stocks on a list from financial newsletter The Kobeissi Letter trade at least 25% below record highs. CoreWeave (CRWV) leads the slide at 76%.Additionally, the S&P 500 has lost over $6 tri
placeholder
Gold and Bitcoin Are Falling. Peter Schiff Sees Opportunities for BothPeter Schiff says gold should not have fallen at all, while Bitcoin (BTC) has not fallen enough. The gold advocate calls the metal’s drop a buying opportunity and Bitcoin’s a selling opportunity.Both
Author  Beincrypto
Nov 20, Fri
Peter Schiff says gold should not have fallen at all, while Bitcoin (BTC) has not fallen enough. The gold advocate calls the metal’s drop a buying opportunity and Bitcoin’s a selling opportunity.Both
goTop
quote